Focus Partners Wealth lowered its position in DaVita Inc. (NYSE:DVA - Free Report) by 95.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,745 shares of the company's stock after selling 84,043 shares during the period. Focus Partners Wealth's holdings in DaVita were worth $560,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in DVA. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita in the fourth quarter valued at about $41,000. Coppell Advisory Solutions LLC increased its holdings in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after buying an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in DaVita during the fourth quarter worth about $55,000. Venturi Wealth Management LLC increased its holdings in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after buying an additional 152 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after buying an additional 131 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on DVA shares. Truist Financial decreased their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, DaVita presently has an average rating of "Hold" and an average price target of $164.50.
Check Out Our Latest Report on DaVita
DaVita Stock Performance
NYSE:DVA traded down $0.22 on Friday, reaching $138.30. 605,497 shares of the company's stock were exchanged, compared to its average volume of 826,271. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The firm has a market cap of $10.44 billion, a price-to-earnings ratio of 12.88, a P/E/G ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60. The stock has a fifty day simple moving average of $145.32 and a 200-day simple moving average of $153.42.
DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the business earned $2.26 earnings per share. The company's quarterly revenue was up 5.0% on a year-over-year basis. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
